←Back to Expert Scholars
Translational Medicine / 转化医学ADC Mechanism and Development
Ulf Grawunder
PhD
🏢NBE Therapeutics🌐Switzerland
Chief Executive Officer
40
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Ulf Grawunder co founded NBE Therapeutics and developed site specific ADC conjugation technology. His work contributed to the development of a ROR1 targeted ADC acquired by Boehringer Ingelheim. He has published on novel payload classes including immune activating ADCs. He is a leader in next generation antibody drug conjugate platforms.
Share:
🧪Research Fields 研究领域
antibody drug conjugates
site specific conjugation
payload design
immuno oncology
drug development
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Ulf Grawunder 的研究动态
Follow Ulf Grawunder's research updates
留下邮箱，当我们发布与 Ulf Grawunder（NBE Therapeutics）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment